Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance reduction or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial

摘要

BackgroundThe aim was to analyze characteristics that predict remission induction and subsequent loss of remission in patients with moderately active rheumatoid arthritis (RA) who received full-dose combination etanercept plus methotrexate induction therapy followed by reduced-dose etanercept or etanercept withdrawal.